<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-11032-2014021 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Targeting BAF complex to reverse HIV latency</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">Currently, there is no drug that can cure HIV. The HIV virus can become latent and therefore difficult to eliminate. There are many ways latent HIV &#x2018;hides&#x2019; in the DNA of our cells. One way is to hide in a cell&#x2019;s folded DNA.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">The aim of this proposal is to investigate if BAF is a highly attractive candidate for targeted inhibition in the development of shock and kill strategies that might lead to cure.

#Aim1. to determine the molecular requirements of BAF-mediated latency, explore role of YY-1 and other sequence-specific transcription factors in BAF recruitment and activity.
#Aim2. to target BAF for inhibition using a novel class of small molecule inhibitors recently available through a formal collaboration (Dr. Palmer, Broad Institute) in spectrum of CD4+ T cell systems reflecting HIV latency available in our laboratory, and determine biomarkers and molecular mechanism of BAF inhibitors.
#Aim3. to examine effectiveness of BAF inhibitors in activation of latent HIV-1 alone and in combination with other latency reversing agents.
#Aim4. to validate and test the effects of candidate small molecule BAF inhibitors for HIV-1 activation in primary memory CD4+ T cells, the in vivo reservoir for latent HIV-1 in 30 people with HIV.

This could contribute to an HIV cure.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">There is no drug that can cure HIV. The HIV virus can become latent and therefore difficult to eliminate. There are many ways latent HIV &#x2018;hides&#x2019; in the DNA of our cells. One way is to hide in a cell&#x2019;s folded DNA. The BAF complex is a group of proteins that play a role in the DNA folding process. EMC researchers aim to determine whether latent HIV can be re-activated by inhibiting the BAF complex.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientific community
people living with HIV</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-09-30" type="1"></activity-date>
  <activity-date iso-date="2017-09-30" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Targeting BAF complex to reverse HIV latency STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2014-09-30"></period-start>
   <period-end iso-date="2017-09-30"></period-end>
   <value currency="EUR" value-date="2014-09-30">250000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">165000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014021, proj.nr. 104655</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-12-30"></transaction-date>
   <value currency="EUR" value-date="2015-12-30">165000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014021, proj.nr. 104655</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-12-22"></transaction-date>
   <value currency="EUR" value-date="2016-12-22">35000</value>
   <description>
    <narrative xml:lang="EN">1490 DOSS 2014021, proj.nr. 104655</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-12-22"></transaction-date>
   <value currency="EUR" value-date="2016-12-22">35000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-05-22"></transaction-date>
   <value currency="EUR" value-date="2018-05-22">50000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-05-23"></transaction-date>
   <value currency="EUR" value-date="2018-05-23">50000</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-24485070">
    <narrative xml:lang="EN">EMC - Biochemistry</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
